BiomX to Present at the H.C. Wainwright Investment Conference
BiomX Inc. (NYSE American: PHGE), a clinical-stage company that is leading the way in natural and engineered phage therapies, is excited to announce its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The session will be led by Jonathan Solomon, the Chief Executive Officer of BiomX, who will provide valuable insights into the company’s innovative strategies for treating chronic diseases using phage technology.
Event Details
This year's conference is set to occur at the Lotte New York Palace Hotel from September 9 to September 11. Jonathan Solomon's presentation is scheduled for September 9, and it will be available on-demand starting at 7:00 AM ET.
Replay Availability
For those who are unable to attend live, a recording of the presentation will be accessible on BiomX’s website in the Events & Presentations section. This replay will be available for 90 days, ensuring that a wider audience can benefit from the information shared.
Meetings and Networking Opportunities
During the conference, Mr. Solomon will also be available for one-on-one meetings. This presents a valuable opportunity for investors and stakeholders to engage directly with the company's leadership. Interested individuals are encouraged to request meetings to discuss the exciting developments at BiomX.
About BiomX
BiomX is at the cutting edge of developing innovative phage therapies designed to make a significant impact on the treatment of chronic diseases. By leveraging the power of naturally occurring bacteriophages, the company tailors treatments to specifically target and eliminate harmful bacteria, addressing critical unmet medical needs. With its proprietary BOLT platform, BiomX identifies and validates bacterial targets, enabling the creation of customized phage cocktails that are uniquely suited to the needs of patients.
Innovative Therapeutic Approaches
As a clinical-stage organization, BiomX is actively progressing its pipeline of phage therapies, each aimed at addressing specific pathogenic bacteria associated with chronic conditions. These therapies offer potential advantages over traditional antibiotic treatments, striving for a more efficient and targeted method for managing bacterial infections.
Contact Information
If you wish to learn more about BiomX and its forward-thinking strategies in phage therapy, please do not hesitate to reach out:
BiomX, Inc.
Assaf Oron
+972-54-2228901
assafo@biomx.com
Investors:
CORE IR
Peter Seltzberg
peters@coreir.com
Frequently Asked Questions
What is BiomX focusing on at the investment conference?
BiomX will provide an overview of its innovative phage therapies aimed at treating chronic diseases.
When can attendees access the presentation?
The on-demand presentation will be available starting at 7:00 AM ET on September 9.
How can I request a meeting with the CEO?
Individuals interested in meeting with Jonathan Solomon during the conference can do so through a registration process.
What is the BOLT platform?
BOLT, which stands for BacteriOphage Lead to Treatment, is BiomX's proprietary platform designed for customizing phage therapies.
What makes phage therapy different from traditional antibiotics?
Phage therapy specifically targets harmful bacteria, providing a potential alternative to antibiotics that often disrupt beneficial flora and contribute to antibiotic resistance.
